MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) are scheduled to reverse split on Tuesday, January 28th. The 1-10 reverse split was announced on Tuesday, January 21st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

MiNK Therapeutics Trading Down 3.5 %

NASDAQ:INKT opened at $0.98 on Friday. The firm has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $0.77. The stock has a market capitalization of $38.64 million, a PE ratio of -2.50 and a beta of 0.10. MiNK Therapeutics has a 1-year low of $0.46 and a 1-year high of $1.90.

Wall Street Analyst Weigh In

Several research firms have recently commented on INKT. Robert W. Baird decreased their target price on MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of MiNK Therapeutics in a research report on Friday, November 15th.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC grew its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.